Manuele Casale
Campus Bio-Medico University, Italy
Title: Topical hyaluronic acid in rhinitis medicamentosa: Could our perspective be changed?
Biography
Biography: Manuele Casale
Abstract
Background & Aim: This study was designed to prospectively evaluate the role of nebulized hyaluronic acid (HA) as a treatment for patients with rhinitis medicamentosa (RM). RM is a pathological condition of the nasal mucosa induced by prolonged, excessive or improper use of topical decongestants.
Methods: Twenty-five (25) patients were treated with HA nebulized via Spray-sol twice a day (morning and evening) for 10-days (T1). Subsequently, after three days of washout, patients were treated with physiological saline nebulized via Spray-sol twice a day (morning and evening) for 10 days (T2).
Results: The HA Spray-sol treatment group significantly improved visual analogue scale (VAS) scores, whereas there was no statistically significant difference in the saline Spray-sol treatment group, results confirmed by the anterior active rhinomanometry (AAR) data. An improvement in the Global Rhinitis Score (GRS) was recorded in both groups, but plus in HA Spray-sol treatment group. Both groups showed a significant reduction in mucosal edema and nasal secretions. Patients treated with HA Spray-sol reduced or even eliminated (11/25 patients) the use of topical decongestant within 10 days of treatment with HA.
Conclusion: The results of this study suggest nebulized topical 9-mg sodium hyaluronate plays a pivotal role in the management of RM.